NASDAQ:NEXI NexImmune (NEXI) Stock Price, News & Analysis → The Weight Loss Pill That Could Disrupt a $32 Billion Industry (From Behind the Markets) (Ad) Free NEXI Stock Alerts $3.41 -0.18 (-5.01%) (As of 12:05 PM ET) Add Compare Share Share Today's Range$3.41▼$3.7150-Day Range$3.12▼$6.7852-Week Range$1.25▼$28.69Volume19,721 shsAverage Volume1.56 million shsMarket Capitalization$4.67 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get NexImmune alerts: Email Address Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About NexImmune Stock (NASDAQ:NEXI)NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a candidate targeted against HPV-associated malignancies, which is in preclinical stage. The company was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.Read More NEXI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NEXI Stock News HeadlinesMay 2, 2024 | americanbankingnews.comSpyre Therapeutics (NASDAQ:SYRE) and NexImmune (NASDAQ:NEXI) Head to Head ContrastApril 17, 2024 | investorplace.comNEXI Stock Earnings: NexImmune Reported Results for Q4 2023May 8, 2024 | Unstoppable Prosperity (Ad)“Crash Insurance” For Your RetirementWhen it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. April 16, 2024 | theglobeandmail.comAcute Myeloid Leukemia Market Size is Expected to Grow by 2032 | DelveInsightApril 15, 2024 | msn.comPortage mulls company closure, pauses enrolment for lead clinical programmeApril 2, 2024 | msn.comXilio fires 21% of its workforce and reprioritises pipelineFebruary 7, 2024 | msn.comNexImmune Announces New Offerings in Recent Press ReleaseFebruary 6, 2024 | markets.businessinsider.comNexImmune Announces Closing of $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesMay 8, 2024 | Unstoppable Prosperity (Ad)“Crash Insurance” For Your RetirementWhen it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. February 6, 2024 | msn.comNexImmune Secures Funding Through Equity and Warrant SalesFebruary 3, 2024 | msn.comNexImmune Ends Stock Sale Agreement, Raises $5.1 MillionFebruary 2, 2024 | msn.comNexImmune slips after securities offeringFebruary 2, 2024 | finance.yahoo.comNexImmune Announces $3.67 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJanuary 13, 2024 | nasdaq.comNexImmune, Inc. Common Stock (NEXI)January 9, 2024 | investorplace.comNexImmune (NEXI) Stock Rockets 80% Ahead of Potential LiquidationDecember 26, 2023 | bizjournals.comNexImmune's future in limbo as Gaithersburg biotech extends liquidation voteDecember 10, 2023 | ca.finance.yahoo.comNexImmune, Inc. (NEXI) Stock Price, News, Quote & History - Yahoo FinanceDecember 1, 2023 | investorplace.comNEXI Stock Halted: What’s Going on With NexImmune Shares Today?December 1, 2023 | investorplace.comWhy Is NexImmune (NEXI) Stock Up 353% Today?November 23, 2023 | morningstar.comNexImmune Inc Ordinary Shares NEXINovember 8, 2023 | bizjournals.comGaithersburg’s NexImmune prepares to shut down, lay off ‘substantially all’ employeesNovember 6, 2023 | msn.comWhat's Going On With Neximmune (NEXI) Stock Monday?November 3, 2023 | msn.comWhy Neximmune (NEXI) Stock Is Getting HammeredNovember 3, 2023 | marketwatch.comNexImmune Shares Slide Premarket as Biotech Says It Will LiquidateOctober 24, 2023 | finance.yahoo.comNexImmune, Yale, and JDRF Extend Research Partnership for Type 1 DiabetesOctober 19, 2023 | finance.yahoo.comNexImmune Announces Presentations at The Society for Immunotherapy of Cancer’s 38th Annual MeetingOctober 18, 2023 | finanznachrichten.deNexImmune, Inc.: NexImmune Announces 1-for-25 Reverse Stock SplitSee More Headlines Receive NEXI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NexImmune and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/16/2024Today5/08/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:NEXI CUSIPN/A CIK1538210 Webwww.neximmune.com Phone301-825-9810FaxN/AEmployees22Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($30.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,340,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-247.17% Return on Assets-167.39% Debt Debt-to-Equity RatioN/A Current Ratio1.06 Quick Ratio1.06 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.32 per share Price / Book1.08Miscellaneous Outstanding Shares1,370,000Free Float1,105,000Market Cap$4.92 million OptionableNot Optionable Beta2.03 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMs. Kristi Jones R.Ph. (Age 61)CEO, President & Director Comp: $680.44kDr. Mathias Oelke Ph.D. (Age 55)Chief Scientific Officer Comp: $621.26kMr. John Trainer M.B.A. (Age 50)Consultant Comp: $546.13kMr. Karen HaslbeckHead of Human ResourcesDr. Daniel P. BednarikSenior Vice President of Molecular Engineering & Protein DesignDr. Robert Douglas Knight M.D. (Age 73)Chief Medical Officer Comp: $454.77kMr. Chad RubinSenior Vice President of Corporate AffairsDr. Jack A. Ragheb M.D.Ph.D., Senior Vice President of Translational ScienceMr. Matthew SchillerHead of Business DevelopmentMore ExecutivesKey CompetitorsSeelos TherapeuticsNASDAQ:SEELZyVersa TherapeuticsNASDAQ:ZVSAKazia TherapeuticsNASDAQ:KZIASynaptogenixNASDAQ:SNPXPetros PharmaceuticalsNASDAQ:PTPIView All CompetitorsInsiders & InstitutionsPNC Financial Services Group Inc.Sold 303,399 shares on 3/22/2024Ownership: 1.192%Alan S RoemerSold 3,833 sharesTotal: $8,279.28 ($2.16/share)View All Insider TransactionsView All Institutional Transactions NEXI Stock Analysis - Frequently Asked Questions How have NEXI shares performed in 2024? NexImmune's stock was trading at $2.22 at the start of the year. Since then, NEXI stock has increased by 61.7% and is now trading at $3.59. View the best growth stocks for 2024 here. Are investors shorting NexImmune? NexImmune saw a decrease in short interest during the month of April. As of April 15th, there was short interest totaling 8,100 shares, a decrease of 54.5% from the March 31st total of 17,800 shares. Based on an average daily volume of 608,800 shares, the short-interest ratio is presently 0.0 days. Currently, 0.9% of the company's shares are sold short. View NexImmune's Short Interest. When is NexImmune's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our NEXI earnings forecast. How were NexImmune's earnings last quarter? NexImmune, Inc. (NASDAQ:NEXI) released its quarterly earnings results on Tuesday, April, 16th. The company reported ($4.99) earnings per share for the quarter. When did NexImmune's stock split? NexImmune shares reverse split before market open on Thursday, October 19th 2023. The 1-25 reverse split was announced on Wednesday, October 18th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, October 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did NexImmune IPO? NexImmune (NEXI) raised $75 million in an initial public offering on Friday, February 12th 2021. The company issued 4,700,000 shares at $15.00-$17.00 per share. Barclays, Cantor, Raymond James and Allen & Co. served as the underwriters for the IPO. How do I buy shares of NexImmune? Shares of NEXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NEXI) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorElon Musk Secret Crypto Plot ExposedCrypto 101 MediaAI “wealth window” is closing June 25thParadigm PressCharles Payne Demystifies OptionsUnstoppable ProsperityShocking: One AI startup's revenue could surge 4,735%Manward PressThe #1 lithium battery stock to have on your radar in 2024!Smallcaps DailyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing[URGENT] DO NOT Touch These AI Stocks!Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NexImmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
